Ajanta Pharma Approves ₹32/Share Interim Dividend, Q1 Revenue Up 25%
Ajanta Pharma reported Q1 FY2027 consolidated revenue of ₹1,626 crore (up 25%) and PAT of ₹334 crore (up 31%). The board approved a first interim dividend of ₹32 per share, amounting to ₹400 crore. The record date is August 5, 2026.
The announcement includes strong financial performance metrics and a substantial dividend payout, which are material events for shareholders.
The company reported strong financial results with significant year-on-year growth in revenue and profit, coupled with the approval of an interim dividend.
Ajanta Pharma Limited announced its financial results for the first quarter ended June 30, 2026, reporting a significant increase in revenue and profit. The company's consolidated revenue from operations stood at ₹1,626 crore, a 25% rise compared to ₹1,303 crore in the same period last year. Profit After Tax (PAT) grew by 31% to ₹334 crore from ₹255 crore.
The Board of Directors has approved the first interim dividend for FY 2027 at ₹32 per share on equity shares of ₹2 face value. This interim dividend amounts to ₹400 crore. The record date for this dividend payment has been fixed as Wednesday, August 5, 2026, with the dividend to be paid on or after August 18, 2026.
The company also provided segment-wise performance details. Branded generics revenue increased by 13% to ₹1,059 crore. US generics revenue saw a substantial jump of 57% to ₹487 crore. Africa institutional business grew by 83% to ₹70 crore.
Ajanta Pharma's R&D expenses for the quarter were ₹66 crore, representing 4% of revenue. The company has a healthy pipeline with 51 products commercialized in the US and 17 ANDAs awaiting approval from the US FDA.
An earnings conference call was scheduled for July 30, 2026, at 16:15 IST to discuss the financial performance and outlook.
What to do with a filing like this
Ajanta Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ajanta Pharma Limited. Read the original for the full detail.